Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million
April 07, 2020 16:05 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with an institutional investor providing...
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 12, 2020 07:30 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 12, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA) reported on March 11, 2020 its financial and operational results for the fourth quarter and year...
Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma
March 05, 2020 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or “the company”) (NASDAQ: IDRA) today announced completion of patient enrollment into ILLUMINATE-301, its...
Idera Pharmaceuticals Provides 2020 Update and Outlook
January 14, 2020 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or Idera or the Company, today is providing an update on its tilsotolimod clinical development program and...
Idera Pharmaceuticals Announces Private Placement Up To $97.7 Million
December 23, 2019 09:15 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an institutional...
Idera Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2019 Financial Results
November 06, 2019 16:01 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037
October 21, 2019 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, 2019...
Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors
September 30, 2019 07:30 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a...
Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie
September 04, 2019 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie,...
Idera Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference
August 30, 2019 12:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the Baird 2019 Global Healthcare Conference on Wednesday,...